Company: NEOG
Filing Date: 2025-09-12
Form Type: DEF 14A
Source: 0000950170-25-114381
Chunk: 54

Company: NEOGEN CORP
Filing Date: 2025-09-12
Form: DEF 14A
Chunk 54
---
 | 78,870 |
| Aashima Gupta              |     |                             | 11,699 |     |               | 78,870 |
| Raphael A. Rodriguez       |     |                             | 11,699 |     |               | 57,536 |
| James P. Tobin             |     |                             | 11,699 |     |               | 78,870 |
| Catherine E. Woteki, Ph.D. |     |                             | 11,699 |     |               | 57,536 |

Non-employee directors receive an annual retainer of $55,000 (paid quarterly), with the Chair of the Board paid an additional $55,000. Members of the Governance, Compensation, and Science, Technology, and Innovation committees are paid $7,500 annually for such committee service, while members of the Audit Committee receive $10,000 annually. The Chairs of the Governance, Compensation, and Science, Technology, and Innovation committees are paid an additional $7,500 annually for their service in those Chair roles, while the Chair of the Audit Committee is paid an additional $10,000 annually. Board members receive an additional $165,000 in equity-based compensation, split equally between non-qualified options to purchase Company stock, with three-year ratable vesting and seven-year lives, and RSUs, with three-year ratable vesting. These awards are granted on the date of election to, or commencement of annual service on, the Board. In all cases, grant prices are equal to the closing price on the day of the grant. The Company does not reprice options and does not “reload”—which means the recipient is only able to exercise the number of shares in the original stock option grant.

| Neogen Corporation | 2025 Proxy Statement | 53 |

#### Equity Compensation Plan Information
Equity Compensation Plan Information The following table shows the number of shares of common stock issuable upon the exercise of outstanding stock options and RSUs, the weighted average exercise price of outstanding stock options and RSUs, and the number of shares of common stock remaining available for future issuance, excluding shares of common stock issuable upon exercise of outstanding stock options or RSUs, in each case as of May 31, 2025.

| Plan Category                                              | Securities to be issued upon exercise of outstanding options |           |     | Weighted-average exercise price of outstanding options |       |     | Securities remaining available for future issuance under equity compensation plans |            |
|:-----------------------------------------------------------